REporting recommendations for tumor MARKer prognostic studies (REMARK)

Breast Cancer Research and Treatment

Volumn 100, Issue 2, 2006, Pages 229-235

  McShane, Lisa M ^a   Altman, Douglas G ^b   Sauerbrei, Willi ^c   Taube, Sheila E ^a   Gion, Massimo ^d   Clark, Gary M ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Ctro Regionale Specializzato P   (Italy)

^e OSI PHARMACEUTICALS INC   (United States)

Author keywords

EORTC; Guidelines; NCI; Prognostic; REMARK; Tumor markers

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

BIOMEDICAL RESEARCH; GUIDELINES; HUMANS; NEOPLASMS; PROGNOSIS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 33750310901     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9242-8     Document Type: Article

References (42)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM et al (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466
2. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM et al for the American Society of Clinical Oncology Tumor Markers Expert Panel (2001). 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878
3. Schilsky RL, Taube SE (2002) Introduction: Tumor markers as clinical cancer tests - are we there yet? Semin Oncol 29:211-212
4. McGuire WL (1991) Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 83:154-155
5. Fielding LP, Fenoglio-Preiser CM, Freedman LS (1992) The future of prognostic factors in outcome prediction for patients with cancer. Cancer 70:2367-2377
6. Burke HB, Henson DE (1993) Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72:3131-3135
7. Concato J, Feinstein AR, Holford TR (1993) The risk of determining risk with multivariable models. Ann Intern Med 118:201-210
8. Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219
9. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69:979-985
10. Gasparini G (1998) Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Res Treat 52:321-331
11. Hall PA, Going JJ (1999) Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 35:489-494
12. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA (2002) Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 12:1-6
13. Thor AD, Liu S, Moore DH II, Edgerton SM (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17:470-477
14. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, DiLeo A et al (2000) Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 113:675-682
15. McShane LM, Aamodt R Cordon-Cardo C, Cote R, Faraggi D, Fradet Y et al and the National Cancer Institute Bladder Tumor Marker Network (2000). Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 6:1854-1864
16. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K et al (2002) Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 94:852-854
17. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857
18. Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72:511-518
19. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122:1037-1057
20. Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235:10-26
21. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D et al (2003) Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88:1191-1198
22. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR et al (2003) A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 39:19-30
23. Burton A, Altman DG (2004) Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 91:4-8
24. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22:529-536
25. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR et al (2004) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10:4-12
26. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52:289-303
27. Gion M, Boracchi P, Biganzoli E, Daidone MG (1999) A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int J Biol Markers 14:123-133
28. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. In: Egger M, Davey Smith G, Altman DG (eds) Systematic reviews in health care. Meta-analysis in context. 2nd edn. BMJ Books, London pp 228-247
29. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323:224-228
30. McShane LM, Simon R (2001) Statistical methods for the analysis of prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch (eds) Prognostic factors in cancer. 2nd edn. Wiley-Liss, New York pp 37-48
31. Simon R (2001) Evaluating prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch (eds) Prognostic factors in cancer. 2nd edn. Wiley-Liss, New York pp 49-56
32. Biganzoli E, Boracchi P, Marubini E (2003) Biostatistics and tumor marker studies in breast cancer: design, analysis and interpretation issues. Int J Biol Markers 18:40-48
33. Schumacher M, Hollander N, Schwarzer G, Sauerbrei W (2006) Prognostic factor studies. In: Crowley J, Ankerst DP (eds) Handbook of statistics in clinical oncology. Boca Raton: Chapman & Hall/CRC Press, pp 289-333
34. Moher D, Schulz KF, Altman D for the CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 285:1987-1991
35. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1-6
36. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835
37. Hilsenbeck SG, Clark GM, McGuire WL (1992) Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197-206
38. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D for the QUOROM Group (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354:1896-1900
39. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012
40. Hammond ME, Taube SE (2002) Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 29:213-221
41. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D et al (2001) for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134:663-694
42. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al (2003) Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7-18